EMA Authorised: Tesavel (sitagliptin) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Tesavel (sitagliptin) by Merck Sharp & Dohme B.V. for treatment of type 2 diabetes mellitus in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesavel (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 28/11/2025